Home  »  Companies   »  Here’s Our Rant About Catalyst Biosciences I...

Here’s Our Rant About Catalyst Biosciences Inc. (CBIO)

Catalyst Biosciences Inc. (NASDAQ:CBIO) went up by 10.00% from its latest closing price compared to the recent 1-year high of $0.40. The company’s stock price has collected 16.61% of gains in the last five trading sessions.

Is It Worth Investing in Catalyst Biosciences Inc. (NASDAQ :CBIO) Right Now?

Catalyst Biosciences Inc. (NASDAQ:CBIO) scored a price-to-earnings ratio above its average ratio, recording 0.79 x from its present earnings ratio. Plus, the 36-month beta value for CBIO is at 0.93.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $3.00. CBIO currently public float of 27.91M and currently shorts hold a 3.43% ratio of that float. Today, the average trading volume of CBIO was 987.42K shares.

CBIO’s Market Performance

CBIO stocks went up by 16.61% for the week, with a monthly drop of -4.05% and a quarterly performance of -16.82%, while its annual performance rate touched 185.16%. The volatility ratio for the week stands at 10.12% while the volatility levels for the past 30 days are set at 10.20% for Catalyst Biosciences Inc. The simple moving average for the period of the last 20 days is -8.75% for CBIO stocks with a simple moving average of 10.23% for the last 200 days.

Analysts’ Opinion of CBIO

Many brokerage firms have already submitted their reports for CBIO stocks, with Stephens repeating the rating for CBIO by listing it as a “Overweight.” The predicted price for CBIO in the upcoming period, according to Stephens is $19 based on the research report published on April 29th of the previous year 2021.

Piper Sandler, on the other hand, stated in their research note that they expect to see CBIO reach a price target of $15. The rating they have provided for CBIO stocks is “Overweight” according to the report published on February 10th, 2021.

Raymond James gave a rating of “Outperform” to CBIO, setting the target price at $20 in the report published on May 21st of the previous year.

CBIO Trading at -9.52% from the 50-Day Moving Average

After a stumble in the market that brought CBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.19% of loss for the given period.

Volatility was left at 10.20%, however, over the last 30 days, the volatility rate increased by 10.12%, as shares sank -39.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.50% lower at present.

During the last 5 trading sessions, CBIO rose by +16.61%, which changed the moving average for the period of 200-days by -53.26% in comparison to the 20-day moving average, which settled at $0.4684. In addition, Catalyst Biosciences Inc. saw -9.05% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for CBIO

Equity return is now at value 26.90, with 22.60 for asset returns.

Is Hayward Holdings Inc. (HAYW) a Keeper?

Hayward Holdings Inc. (NYSE:HAYW) went up by 3.41% from its latest closing price compared to the recent 1-year high of $20.13. The company’s stock price